Idecabtagene vicleucel

Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy used to treat multiple myeloma. It is a B-cell maturation antigen directed chimeric antigen receptor T-cell therapy, made by genetically modifying a patient's own T-cells so they recognize and attack myeloma cells that carry the BCMA protein. It is indicated for adults with relapsed or refractory multiple myeloma who have already received at least two prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody. The United States Food and Drug Administration approved it in March 2021, its first approval of a cell-based gene therapy for multiple myeloma, and the European Union approved it in August 2021. It is developed by Celgene Corporation, a Bristol-Myers Squibb company.